Science & Technology

Overview

NEUMANN is a data driven company. Up to date over 7,000 cervical samples were tested in a clinical trial the company is sponsoring. This is a tremendous opportunity to show the value of NEUMANN’s CONFIDENCE™ tests.

Read more


Why Pap test needs improvement

Over a 100 million women are screened for cervical cancer each year in the Western World and through these programs cervical cancer was reduced by 50%, but the system lacks efficiency, automation and objectivity.

Read more


Early results of the clinical trial - HPV 2015 presentation

Epigenetic markers on the horizon: how to triage hrHPV positive women? Presented at the 30th International Papillomavirus Conference, Sept 17-21 2015, Lisbon, Portugal.

Read more


CONFIDENCE™ HPV validation results

In the clinical study the CONFIDENCE™ HPV test showed high agreement with the comparator test.

Read more


Personalized Risk Assessment for Every Women

NEUMANN has a new approach: personalized risk assessment for every women. The CONFIDENCE™ Marker can establish the risk of every patient for dysplasia.

Read more


3D Demonstration of Cervical Cancer Risk Map

The presented 3D risk assessment map shows the probability of an underlying CIN2+ based on the patient’s age and the epigenetic test result.

Read more